DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Kreisl TN, Kim L, Moore K et al.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J Clin Oncol 2009;
27: 740-745
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.